Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BCDAD / BioCardia, Inc. - Stock Institutional Ownership and Shareholders -

BioCardia, Inc. (OTC:BCDAD) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,731,876 shares. Largest shareholders include Opko Health, Inc., Howard Capital Management, and Glenmede Trust Co Na. (73-0)

RXII / RXI Pharmaceuticals Corporation - Stock Institutional Ownership and Shareholders -

RXI Pharmaceuticals Corporation (NASDAQ:RXII) has 18 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 393,637 shares. Largest shareholders include Panagora Asset Management Inc, Opko Health, Inc., Two Sigma Securities, Llc, Millennium Management Llc, Citadel Advisors Llc, Geode Capital Management, Llc, Virtu Financial LLC, Raymond James Financial Services Advisors, Inc. (146-0)

Dish Network, Opko Health Sink into Wednesday’s 52-Week Low Club

2018-01-17 247wallst
January 17, 2018: Here are four stocks trading with heavy volume among 63 equities making new 52-week lows in Wednesday’s session. On the NYSE advancers led decliners by nearly 2 to 1 and on the Nasdaq, advancers led decliners by about the same ratio. (90-2)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-7)

Opko Health, Inc. - All Holdings - 13F 13D 13G Filings -

Opko Health, Inc. has disclosed 10 total holdings in their latest SEC filings. This investor has not filed a 13F, which indicates it has under $100M in Assets Under Management (AUM). This investor has filed 4 activist 13D filings recently, which suggests it takes an active role in influencing management. Opko Health, Inc.'s top industries are "Chemicals And Allied Products" (sic 28) , and "Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks" (sic 38) . (73-1)

Why OPKO Health (OPK) Could Be Positioned for a Slump

2017-11-27 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. (98-4)

OPKO Health: A House Of Cards Tumbling In The Dark

2017-11-17 seekingalpha
A slew of undisclosed or thinly disclosed executive team departures in the diagnostics division, which represents over 82.8% of revenue, could signal business decline and a compliance “house-cleaning”. (73-3)

Cramer's lightning round: Opko Health is a 'neighborhood of pain'

2017-11-16 cnbc
Opko Health Inc.: "Oh my god, the quarter, not good. I mean, this thing has become a genuine house of pain. No, this is like a neighborhood of pain. And until [CEO] Dr. Frost comes on, we're going to back away. We have to. We have to." (207-2)

What Do Versartis (NASDAQ: VSAR)'s Troubles Mean For Opko Health (NASDAQ: OPK)? | Benzinga

2017-11-16 benzinga
Versartis Inc (NASDAQ: VSAR) shares are slumping even as rival Opko Health Inc. (NASDAQ: OPK) is seeing slight strength, though not proportionate to the sell-off seen in Versartis shares. (144-4)

General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club

2017-11-14 247wallst
November 14, 2017: Here are four stocks trading with heavy volume among 170 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners and advancers by less than 4 to 3. (333-3)

The Interesting Company That Produces An Anti-Aging Pill

2017-11-14 seekingalpha
ChromaDex has a product that can has multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. (79-1)

Billionaires Club Investing In ChromaDex As Revenue Grows

2017-11-10 seekingalpha
Recent change in company strategy includes sale of their lab business and more focus on Niagen (NR) sales. (147-5)

OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3

2017-11-10 zacks
OPKO Health, Inc. (OPK - Free Report) reported loss of 8 cents per share in the third quarter of 2017, compared with a loss of 3 cents a year ago. Moreover, the loss was wider than the Zacks Consensus Estimate of a loss of 5 cents. (83-0)

OPKO Health's (OPK) CEO Phillip Frost on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Welcome to the OPKO Health Third Quarter Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded November 8, 2017. (75-2)

4 Medical Device Stocks to Top Q3 Earnings

2017-11-01 zacks
We are in the thick of the earnings season with more than 64.2% of the index’s total market capitalization having already released their quarterly numbers. Meanwhile, in the MedTech space, uncertainty related to the Trump administration’s Obamacare repeal & replacement effort continues to make headlines. The latest uproar is related to the President’s newly-released executive order, designed to provide affordable quality healthcare to the nation. (104-2)

OPK : Opko Health Stock Analysis and Research Report

Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...

Click for full article
CUSIP: 68375N103